Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
← catalyst calendarSponsored by aTyr Pharma, Inc. (industry) · ATYR — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
25estimated
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-26 | actual | When the study began enrolling |
| Primary completion | Apr 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Interstitial Lung Disease
Interventions
- Drug: efzofitimod 450 mg
- Drug: efzofitimod 270 mg
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFAbsolute change from baseline in forced vital capacity (FVC) in mL
measured 24 weeks
Annual rate of decline in FVC in mL
measured 24 weeks
Annual rate of decline in FVC in percent predicted
measured 24 weeks
Change in HRCT fibrosis score
measured Baseline to Week 24
Permalink · ATYR's whole pipeline · Catalyst calendar · Every registered study · What changed